$Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome$
Código QR

Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome

A 44-year-old woman was found to have elevated aminotransferases, twice the upper limit of normal. Liver biopsy demonstrated a mixed inflammatory process suggestive of both primary biliary cirrhosis and autoimmune hepatitis (AIH). Prednisone and azathioprine were started, with normalization of amino...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carey,Elizabeth J, Somaratne,Krishni, Rakela,Jorge
Lenguaje:	English
Publicado:	Sociedad Médica de Santiago 2011
Materias:	Anemia hemolytic autoimmune Evans syndrome Hepatitis Rituximab
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011001100015
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872011001100015
record_format	dspace
spelling	oai:scielo:S0034-988720110011000152012-02-08Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndromeCarey,Elizabeth JSomaratne,KrishniRakela,Jorge Anemia hemolytic autoimmune Evans syndrome Hepatitis autoimmune Rituximab A 44-year-old woman was found to have elevated aminotransferases, twice the upper limit of normal. Liver biopsy demonstrated a mixed inflammatory process suggestive of both primary biliary cirrhosis and autoimmune hepatitis (AIH). Prednisone and azathioprine were started, with normalization of aminotransferases. Six months later, she returned with worsening pruritus and re-evaluation demonstrated probable reactivation of AIH with acute elevation of liver injury tests. Repeat liver biopsy was suggestive of a flare of AIH which did not respond to prednisone, azathioprine, or mycophenolate mofetil. One month later the patient was hospitalized for sudden onset of anemia and thrombocytopenia, suggestive of autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura consistent with Evans syndrome. Rituximab was initiated and mycophenolate mofetil discontinued. After one infusion of rituximab, liver injury tests significantly improved. Within four weeks of rituximab infusion (4 doses) the patient's Evans syndrome completely resolved with normal hemoglobin and platelet levels; aminotransferases also significantly improved to less than twice the upper limit of normal.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.139 n.11 20112011-11-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011001100015en10.4067/S0034-98872011001100015
institution	Scielo Chile
collection	Scielo Chile
language	English
topic	Anemia hemolytic autoimmune Evans syndrome Hepatitis autoimmune Rituximab
spellingShingle	Anemia hemolytic autoimmune Evans syndrome Hepatitis autoimmune Rituximab Carey,Elizabeth J Somaratne,Krishni Rakela,Jorge Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome
description	A 44-year-old woman was found to have elevated aminotransferases, twice the upper limit of normal. Liver biopsy demonstrated a mixed inflammatory process suggestive of both primary biliary cirrhosis and autoimmune hepatitis (AIH). Prednisone and azathioprine were started, with normalization of aminotransferases. Six months later, she returned with worsening pruritus and re-evaluation demonstrated probable reactivation of AIH with acute elevation of liver injury tests. Repeat liver biopsy was suggestive of a flare of AIH which did not respond to prednisone, azathioprine, or mycophenolate mofetil. One month later the patient was hospitalized for sudden onset of anemia and thrombocytopenia, suggestive of autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura consistent with Evans syndrome. Rituximab was initiated and mycophenolate mofetil discontinued. After one infusion of rituximab, liver injury tests significantly improved. Within four weeks of rituximab infusion (4 doses) the patient's Evans syndrome completely resolved with normal hemoglobin and platelet levels; aminotransferases also significantly improved to less than twice the upper limit of normal.
author	Carey,Elizabeth J Somaratne,Krishni Rakela,Jorge
author_facet	Carey,Elizabeth J Somaratne,Krishni Rakela,Jorge
author_sort	Carey,Elizabeth J
title	Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome
title_short	Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome
title_full	Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome
title_fullStr	Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome
title_full_unstemmed	Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome
title_sort	successful rituximab therapy in refractory autoimmune hepatitis and evans syndrome
publisher	Sociedad Médica de Santiago
publishDate	2011
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872011001100015
work_keys_str_mv	AT careyelizabethj successfulrituximabtherapyinrefractoryautoimmunehepatitisandevanssyndrome AT somaratnekrishni successfulrituximabtherapyinrefractoryautoimmunehepatitisandevanssyndrome AT rakelajorge successfulrituximabtherapyinrefractoryautoimmunehepatitisandevanssyndrome
_version_	1718436599162732544

Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome

Ejemplares similares